Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Thames Water finance chief stepping down

(Sharecast News) - Thames Water's chief financial officer Alastair Cochran will leave the company at the end of March, it was announced on Friday, marking a significant leadership change as the debt-laden utility pushed ahead with efforts to stabilise its finances. Cochran, who joined in 2021 and also served briefly as joint chief executive, would step down from both the executive team and the board.

His departure came at a critical moment for the UK's largest water and sewage company, which was attempting to recapitalise amid nearly £20bn in debt and mounting regulatory scrutiny over environmental performance.

The company recently secured a £3bn emergency loan to stave off insolvency, though the funds were not expected to be available until early April.

Cochran played a central role in the early stages of Thames Water's financial restructuring and equity raise, and was instrumental in negotiating the rescue loan that provided a short-term lifeline.

He also helped develop a new business plan aimed at addressing long-standing infrastructure and environmental challenges, which had led to heavy criticism and fines from regulators.

Stuart Thom, currently director of group finance, was appointed interim finance chief while the company searched for a permanent successor.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.